secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2026-09-10T20:46:58+00:00
Accession:  0001628280-26-061383
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q1 revenue up 8.8% to $15.2M; adjusted EBITDA $671K vs $59K
------------------------------------------------------------------------------

- Revenue $15.2M, +8.8% YoY; oncology services margin improved to 51% from 43%.
- Adjusted EBITDA $671K vs $59K; net loss narrowed to $426K from $466K.
- Sales & marketing expense up 66.6% to $3.1M on commercial expansion.
- Cash $4.4M, no debt; net cash used in ops ~$492K.
- R&D up 12.6% to $2.3M, driven by Corellia share-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/0001628280-26-061383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/csbr-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-061383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer